Could a simple pill tame long COVID's immune chaos?

NCT ID NCT07189936

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a drug called 2-HOBA can reduce immune system overactivity in people with Long COVID who also have POTS (a condition causing rapid heart rate upon standing). The study will enroll 50 participants and randomly assign them to receive either 2-HOBA or a placebo for 28 days. Researchers will measure immune markers and symptoms to see if the drug helps calm the persistent immune response thought to drive many Long COVID symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
2-hydroxybenzylamine (2-HOBA)
What this could lead to
If it works, this could point toward a treatment that reduces immune system overactivity and improves symptoms like fatigue and rapid heart rate in Long COVID POTS patients.
What could go wrong
This is a small early-phase trial with only 50 participants, so results may not apply to everyone. The drug may not reduce immune markers or improve symptoms better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cyndya Shibao

    RECRUITING

    Nashville, Tennessee, 37027, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.